Compile Data Set for Download or QSAR
maximum 50k data
Found 175 Enz. Inhib. hit(s) with all data for entry = 125
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161987(US9669028, 13 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161987(US9669028, 13 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161987(US9669028, 13 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161987(US9669028, 13 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161987(US9669028, 13 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161987(US9669028, 13 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161988(US9669028, 19 5-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM161988(US9669028, 19 5-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162018(US9669028, 22 N-(1-(4-fluorobenzyl)piperidin-3-yl)...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162018(US9669028, 22 N-(1-(4-fluorobenzyl)piperidin-3-yl)...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162018(US9669028, 22 N-(1-(4-fluorobenzyl)piperidin-3-yl)...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162019(US9669028, 26 N-(1-(3,4-difluorobenzylpiperidin-3-...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162019(US9669028, 26 N-(1-(3,4-difluorobenzylpiperidin-3-...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162020(US9669028, 27 N-(1-(4-chlorobenzyl)piperidin-3-yl)...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162020(US9669028, 27 N-(1-(4-chlorobenzyl)piperidin-3-yl)...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162020(US9669028, 27 N-(1-(4-chlorobenzyl)piperidin-3-yl)...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162026(US9669028, 28 N-(1-(3,4-difluorobenzyl)piperidin-3...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162026(US9669028, 28 N-(1-(3,4-difluorobenzyl)piperidin-3...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162026(US9669028, 28 N-(1-(3,4-difluorobenzyl)piperidin-3...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162034(US9669028, 33 3-methyl-5-(6-(2-(4-methylpiperazin-...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162034(US9669028, 33 3-methyl-5-(6-(2-(4-methylpiperazin-...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162034(US9669028, 33 3-methyl-5-(6-(2-(4-methylpiperazin-...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162035(US9669028, 39 1-methyl-N-(6-(3-methyl-1H-pyrazolo[...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162035(US9669028, 39 1-methyl-N-(6-(3-methyl-1H-pyrazolo[...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162035(US9669028, 39 1-methyl-N-(6-(3-methyl-1H-pyrazolo[...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162045(US9669028, 48 1-(6-(3-methyl-1H-pyrazolo[3,4-b]pyr...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162045(US9669028, 48 1-(6-(3-methyl-1H-pyrazolo[3,4-b]pyr...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162228(US9669028, 51 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162228(US9669028, 51 6-(3-methyl-1H-pyrazolo[3,4-b]pyridi...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162229(US9669028, 56 5-(6-(3,3-difluoropyrrolidin-1-yl)py...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162229(US9669028, 56 5-(6-(3,3-difluoropyrrolidin-1-yl)py...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162230(US9669028, 59 2-(4-(6-(3-methyl-1H-pyrazolo[3,4-b]...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162230(US9669028, 59 2-(4-(6-(3-methyl-1H-pyrazolo[3,4-b]...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162230(US9669028, 59 2-(4-(6-(3-methyl-1H-pyrazolo[3,4-b]...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162232(US9669028, 62 (6-(3-methyl-1H-pyrazolo[3,4-b]pyrid...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162232(US9669028, 62 (6-(3-methyl-1H-pyrazolo[3,4-b]pyrid...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162232(US9669028, 62 (6-(3-methyl-1H-pyrazolo[3,4-b]pyrid...)
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162233(US9669028, 65 3-methyl-5-(6-(4-methylpiperazin-1-y...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162233(US9669028, 65 3-methyl-5-(6-(4-methylpiperazin-1-y...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162246(US9669028, 68 N1,N1-dimethyl-N2-(6-(3-methyl-1H-py...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162246(US9669028, 68 N1,N1-dimethyl-N2-(6-(3-methyl-1H-py...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162250(US9669028, 71 N-methyl-6-(3-methyl-1H-pyrazolo[3,4...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162250(US9669028, 71 N-methyl-6-(3-methyl-1H-pyrazolo[3,4...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162250(US9669028, 71 N-methyl-6-(3-methyl-1H-pyrazolo[3,4...)
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162328(US9669028, 77 (6-(3-methyl-1H-pyrazolo[3,4-b]pyrid...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162328(US9669028, 77 (6-(3-methyl-1H-pyrazolo[3,4-b]pyrid...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162331(US9669028, 81 2-(4-((6-(3-methyl-1H-pyrazolo[3,4-b...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162331(US9669028, 81 2-(4-((6-(3-methyl-1H-pyrazolo[3,4-b...)
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162331(US9669028, 81 2-(4-((6-(3-methyl-1H-pyrazolo[3,4-b...)
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Arrien Pharmaceuticals

US Patent
LigandPNGBDBM162332(US9669028, 83 4-(6-(3-methyl-1H-pyrazolo[3,4-b]pyr...)
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 175 total ) | Next | Last >>
Jump to: